Compare Braze Inc (BRZE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Incyte Corporation — how do they compare? Braze Inc trades at $28.27 (market cap $3.18B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 7.7× Braze Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| BRZE | INCY | |
|---|---|---|
Market Cap | $3.18B | $24.54B |
Sector | Technology | Health |
52-Week High | $36.19 | $129.93 |
52-Week Low | $15.79 | $81.61 |
Enterprise Value | $2.87B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRZE trades at $27.68, down 3.72% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth is strong at 30% year-over-year, though the company remains unprofitable with a net margin of -15.51%. Recent news highlights insider selling and a 15% weekly rebound amid AI sector momentum.
The stock offers growth exposure with a consensus price target of $34.78, but risks include persistent losses, competitive pressures, and high valuation multiples. Analyst sentiment is overwhelmingly bullish, yet profitability challenges and insider sales warrant caution for investors seeking near-term returns.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
